Immunotherapy with recombinant human IL-2 (rHuIL-2) after autologous stem cell transplantation (ASCT) for high-risk neuroblastoma (HR-NB).

被引：0
|
作者：
Pession, A
Prete, A
Locatelli, F
Melchionda, F
Messina, C
Bonetti, F
Alvisi, P
Cordero, L
Rondelli, R
Rabusin, M
Favre, BC
Arrighini, A
Paolucci, P
Millanaccio, C
Bernardi, D
Paolucci, G
机构：
[1] Dept Pediat, Bologna, Italy
[2] Univ Pavia, Dept Pediat, I-27100 Pavia, Italy
[3] Univ Turin, Dept Pediat, I-10124 Torino, Italy
[4] Univ Padua, Dept Pediat, Padova, Italy
[5] Dept Pediat, Genova, Italy
[6] Dept Pediat, Trieste, Italy
[7] Dept Pediat, Pisa, Italy
[8] Dept Pediat, S Giovanni Rotondo, Italy
[9] Univ Brescia, Dept Pediat, Brescia, Italy
来源：
BONE MARROW TRANSPLANTATION | 1998年 / 21卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
780
引用
收藏
页码：S222 / S222
页数：1
相关论文
共 50 条
  • [1] Adoptive immunotherapy with recombinant human IL-2 (rHuIL-2) after autologous stem cell transplantation (ASCT) for high-risk neuroblastoma (HR-NB).
    Pession, A
    Prete, A
    Locatelli, F
    Alvisi, P
    Garaventa, A
    Messina, C
    Pierinelli, S
    Bonetti, F
    Cordero, L
    Favre, C
    Arrighini, A
    Rondelli, R
    DeBernandi, B
    Paolucci, G
    EXPERIMENTAL HEMATOLOGY, 1996, 24 (09) : 374 - 374
  • [2] Adoptive immunotherapy with recombinant human IL-2 after autologous bone marrow transplantation for high risk neuroblastoma
    Prete, A
    Rondelli, R
    Locatelli, F
    Pierinelli, S
    Fagioli, F
    Messina, C
    Garaventa, A
    Pession, A
    BONE MARROW TRANSPLANTATION, 2004, 33 : S219 - S219
  • [3] SECONDARY MALIGNANT NEOPLASMS (SMN) AFTER INTENSIVE CHEMOTHERAPY AND TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR HIGH-RISK NEUROBLASTOMA
    Hijiya, Nobuko
    Martin, Alissa
    Schneiderman, Jennifer
    Hatahet, Mohamad
    Rademaker, Alfred
    Helenowski, Irene
    Morgan, Elaine
    Dilley, Kimberley
    Danner-Koptik, Karina
    Shimada, Hiroyuki
    Cohn, Susan
    Kletzel, Morris
    PEDIATRIC BLOOD & CANCER, 2012, 58 (07) : 1086 - 1086
  • [4] Immunotherapy with low dose recombinant interleukin 2 after high-dose chemotherapy and autologous stem cell transplantation in neuroblastoma
    Pession, A
    Prete, A
    Locatelli, F
    Pierinelli, S
    Pession, AL
    Maccario, R
    Magrini, E
    De Bernardi, B
    Paolucci, P
    Paolucci, G
    BRITISH JOURNAL OF CANCER, 1998, 78 (04) : 528 - 533
  • [5] Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation
    Rousseau, RF
    Biagi, E
    Dutour, A
    Yvon, ES
    Brown, MP
    Lin, T
    Mei, ZY
    Grilley, B
    Popek, E
    Heslop, HE
    Gee, AP
    Krance, RA
    Popat, U
    Carrum, G
    Margolin, JF
    Brenner, MK
    BLOOD, 2006, 107 (04) : 1332 - 1341
  • [6] Autologous stem cell transplantation (ASCT) for high-risk pediatric solid tumors
    Fraser, VJ
    Weigel, BJ
    John, PP
    Todd, DE
    Kevin, BS
    Michael, VR
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (02) : 65 - 65
  • [7] IMMUNOTHERAPY AFTER AUTOLOGOUS OR ALLOGENEIC HEMOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HIGH-RISK NEUROBLASTOMA, A SINGLE CENTER EXPERIENCE
    Kazantsev, Ilya
    Gevorgian, Asmik
    Jukhta, Tatiana
    Kozlov, Andrey
    Tolkunova, Polina
    Halipskaya, Margarita
    Bogdanova, Olga
    Galimov, Alexander
    Andreeva, Tatiana
    Subora, Nina
    Yudintseva, Olesya
    Kuga, Polina
    Shvetsov, Alexander
    Safonova, Svetlana
    Punanov, Yuri
    Zubarovskaya, Ludmila
    PEDIATRIC BLOOD & CANCER, 2022, 69 : S221 - S221
  • [8] Retinoic acid (RA) relieves EZH2-mediated epigenetic suppression in high-risk neuroblastoma (HR-NB)
    Banerjee, Deblina
    Liu, Zhihui
    Oh, Doo-Yi
    Cam, Maggie
    Kim, Bong-Hyun
    Thiele, Carol
    CANCER RESEARCH, 2017, 77
  • [9] Autologous stem cell transplantation for high-risk neuroblastoma: the Iranian experience
    Hamidieh, A. A.
    Alimoghaddam, K.
    Huoseini, A.
    Jorjani, H.
    Jalali, A.
    Derakhshandeh, R.
    Ghavamzadeh, A.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S384 - S385
  • [10] Anti-GD2 immunotherapy in adults with high-risk neuroblastoma (HR-NB): The Memorial Sloan Kettering Cancer Center (MSKCC) experience.
    Suzuki, Maya
    Kushner, Brian H.
    Kramer, Kim
    Basu, Ellen M.
    Roberts, Stephen S.
    LaQuaglia, Michael P.
    Cheung, Nai-Kong V.
    Modak, Shakeel
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345